At a Glance
- Company: Thermo Fisher Scientific Inc. (Pharma Services)
- Location: Waltham, Massachusetts, USA
- Headline figures: Multiple new contracts (undisclosed value)
- Focus area: CDMO services for reshoring production from Europe/Asia
- Next steps: Tailwinds in 2027–2028 from accelerated projects
What happened?
Thermo Fisher Scientific’s pharmaceutical services business has secured multiple contracts to support customers relocating production from Europe or Asia to the United States. CEO Marc Casper shared the development at the J.P. Morgan Healthcare Conference, citing a “very big focus on reshoring” as a key growth driver.
Why does it matter?
President Donald Trump’s policies—100% tariffs on imported drugs (delayed but looming) and MFN pricing mandates—have spurred fast‑tracked reshoring, price concessions and DTC strategies. Thermo’s CDMO network benefits from this shift, with pharma services poised for high single‑digit growth through expanded capacity like the Ridgefield, New Jersey site acquired from Sanofi.
Who’s behind it?
Thermo Fisher is the world’s largest CDMO provider, with integrated capabilities across API, sterile injectables, biologics and fill‑finish. Its pharma services unit serves major pharmas reshoring to mitigate tariff risk and secure US supply chains.
How was it achieved?
Contracts cover production relocation, leveraging Thermo’s US footprint and regulatory expertise; Ridgefield acquisition was explicitly for “capital expansion to help customers reshore”. Improved biotech funding and pharma confidence in the administration further support pipeline investment.
What’s next?
Reshoring tailwinds accelerate in 2027–2028, boosting pharma services growth. Thermo reports Q4/full‑year 2025 results on 29 January 2026.
What are people saying?
CEO Marc Casper: “There’s a very big focus on reshoring more production… We’re winning new business.” Evercore ISI’s Vijay Kumar: “Thermo Fisher’s messaging was constructive… optimism without raising the bar for 2026.”